What outcomes were reported for elderly participants taking Polivy?
The provided information does not include any specific results or subgroup data for elderly participants using Polivy (polatuzumab vedotin). Without study details or published subgroup tables for older adults, it is not possible to say how Polivy affects that age group.
Does Polivy have age-specific safety or dose changes?
The provided information does not state whether dosing, monitoring, or safety findings differ for elderly participants receiving Polivy.
What to look up to answer this for older adults
To determine how Polivy affects elderly participants, you would typically look for:
- Trial subgroup results by age (for example, outcomes split into <65 vs. ≥65, or similar cutoffs)
- Adverse event rates in older vs. younger groups, including serious events, infections, and treatment discontinuations
- Any dose modifications or discontinuation patterns for older participants
- Pharmacokinetic or exposure-efficacy analyses by age (if available)
Can results from the overall population be applied to elderly participants?
Not reliably. Older adults can have different baseline risk (frailty, comorbidities, organ function) and may experience different tolerability or toxicity even when overall efficacy is similar. Age-specific subgroup reporting is the most direct way to understand the effect.
Share the missing details so the answer can be specific
If you paste the relevant excerpt (e.g., a study section or table) or tell me which trial or publication you mean (study name/ID and the age breakdown used), I can summarize exactly what it says about elderly participants on Polivy.